Tempero Bio, an Oakland, CA-based clinical-stage biopharmaceutical company developing treatments for substance use disorders, raised $70M in Series B funding.
The round was led by 8VC with participation from Aditum Bio, Khosla Ventures, and other investors.
The company intends to use the funds to advance TMP-301 through two Phase 2 clinical trials for alcohol use disorder and cocaine use disorder, as well as Phase 3-enabling activities and preclinical studies for additional indications and formulations.
Led by Ricardo Dolmetsch, Ph.D., President and CSO, Tempero Bio is a clinical-stage biopharmaceutical company committed to developing innovative treatments for substance use disorders—chronic, relapsing brain diseases with limited pharmacologic solutions. It is dedicated to advancing science-driven therapies that redefine treatment paradigms.
Dr. John Wagner will be joining Tempero Bio as Chief Medical Officer.
FinSMEs
24/03/2025